Baxdrostat

Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension. It is an aldosterone synthase inhibitor.

Mechanism of action

Aldosterone dysregulation contributes significantly to the pathogenesis of resistant hypertension. While conventional drugs act by blocking the mineralocorticoid receptor, baxdrostat, an aldosterone synthase inhibitor, targets the aldosterone synthesis directly.

Clinical trials

BrigHTN

In adults with treatment-resistant hypertension, treatment with baxdrostat at doses of 1 mg or 2 mg daily produced significantly greater reductions in systolic blood pressure over 12 weeks compared to placebo.

BaxHTN

BaxHTN is a phase 3 trial. It found that adding once-daily baxdrostat to standard antihypertensive therapy led to significantly greater reductions in seated systolic blood pressure at 12 weeks compared with placebo, in adults with uncontrolled or resistant hypertension.